X

Trial Profile

Heart Rate Reduction by IVabradine for Improvement of ENDothELial Function in Patients With Coronary Artery Disease: the RIVENDEL Study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 07 Mar 2017

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ivabradine (Primary)
Indications Coronary artery disease
Focus Biomarker; Pharmacodynamics
Acronyms RIVENDEL

Most Recent Events

02 Sep 2015 Results presented at the ESC Congress 2015: Annual Congress of the European Society of Cardiology
02 Sep 2015 Primary endpoint ( at T2 and T3-flow-mediated dilatation and nitroglycerin-mediated dilatation) has been met as per results presented at the ESC Congress 2015: Annual Congress of the European Society of Cardiology
12 Aug 2013 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com